Otsuka Holdings Co., Ltd. Stock price

Equities

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange 01:00:00 2024-02-26 am EST 5-day change 1st Jan Change
5,772 JPY +2.38% Intraday chart for Otsuka Holdings Co., Ltd. +4.72% +9.13%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 2,019B 13.42B Sales 2024 * 2,079B 13.83B Capitalization 3,060B 20.34B
Net income 2023 122B 809M Net income 2024 * 236B 1.57B EV / Sales 2023 1.24 x
Net cash position 2023 375B 2.49B Net cash position 2024 * 591B 3.93B EV / Sales 2024 * 1.19 x
P/E ratio 2023
23.6 x
P/E ratio 2024 *
12.9 x
Employees 33,482
Yield 2023
2.08%
Yield 2024 *
2.12%
Free-Float 79.62%
More Fundamentals * Assessed data
Dynamic Chart
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024 CI
Otsuka Holdings Lowers 2023 Profit Outlook MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range RE
Japan's Nikkei soars to 34-year high on chip shares, earnings RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint MT
Otsuka's drug for Alzheimer's disease agitation fails in late stage study RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023 CI
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study MT
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema MT
Otsuka's Unit Remains as MicroPort Scientific's Thai Distributor Until 2026 MT
Otsuka Unit Buys New York-Based Provider of Women Health Products MT
Nomura Adjusts Otsuka Holdings' Price Target to 6,800 Yen From 6,500 Yen, Keeps at Buy MT
More news
1 day+2.38%
1 week+4.72%
Current month-0.89%
1 month-0.22%
3 months+2.49%
6 months+5.14%
Current year+9.13%
More quotes
1 week
5 506.00
Extreme 5506
5 814.00
1 month
5 030.00
Extreme 5030
5 868.00
Current year
5 030.00
Extreme 5030
5 977.00
1 year
3 827.00
Extreme 3827
5 977.00
3 years
3 827.00
Extreme 3827
5 977.00
5 years
3 224.00
Extreme 3224
5 977.00
10 years
2 773.00
Extreme 2773
5 977.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 08-07-07
Director of Finance/CFO 62 15-02-28
Chairman 59 08-07-07
Members of the board TitleAgeSince
Chief Executive Officer 73 08-07-07
Chairman 59 08-07-07
Director/Board Member 72 19-02-28
More insiders
Date Price Change Volume
24-02-26 5,772 +2.38% 1 237 200
24-02-22 5,638 +0.75% 995,400
24-02-21 5,596 +0.67% 993,400
24-02-20 5,559 +0.85% 862,000
24-02-19 5,512 -1.61% 806,200

Delayed Quote Japan Exchange, February 26, 2024 at 01:00 am EST

More quotes
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
5,638 JPY
Average target price
5,545 JPY
Spread / Average Target
-1.64%
Consensus
  1. Stock
  2. Equities
  3. Stock Otsuka Holdings Co., Ltd. - Japan Exchange
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW